LoadingLoadingCookies show us what works. Privacy
Cookies show us what works. Privacy
LoadingCookies show us what works. Privacy
24 funds hold it · Insiders net selling
Net selling: insiders sold $1.2M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
Unlock the full resultsLast report
Nov 4, 2026
Period ending
Sep 30, 2026
Earnings per share
$2.23 expected
Estimates as of Nov 10, 2026
EPS expected
$2.93 to $2.93
Revenue expected
2 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
| Quarter / reported | Earnings per share | Beat or miss | Revenue / income | Revenue vs last year |
|---|---|---|---|---|
| Sep 30, 2026Reported Nov 4, 2026 | $2.65est. $2.23 | +19.10%beat | $656.4MSEC filing | +0.5%from $653.0M |
| Jun 30, 2026Reported Aug 4, 2026 | $2.62est. $1.75 | +50.13%beat | $651.0MSEC filing | -0.1%from $651.6M |
| Mar 31, 2026Reported Apr 30, 2026 | $1.89est. $1.99 | -4.79%miss | $592.1MSEC filing | +1.1%from $585.4M |
| Dec 31, 2025Reported Feb 12, 2026 | $2.51est. $2.70 | -7.04%miss | $693.2MAlpha Vantage | +3.9%from $667.5M |
| Sep 30, 2025Reported Oct 29, 2025 | $2.26est. $1.93 | +17.10%beat | $653.0MSEC filing | +0.5%from $649.7M |
| Jun 30, 2025Reported Jul 31, 2025 | $2.61est. $1.75 | +49.14%beat | $651.6MSEC filing | +2.1%from $638.5M |
| Mar 31, 2025Reported May 1, 2025 | $2.54est. $1.78 | +42.70%beat | $585.4MSEC filing | -4.2%from $610.8M |
| Dec 31, 2024Reported Feb 13, 2025 | $2.90est. $2.88 | +0.69%in line | $667.5MSEC filing | -2.0%from $681.2M |
Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.
| USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $693.2M | $592.1M | $651.0M | $656.4M |
| Cost of what it sold | $348.0M | $282.7M | $305.2M | $327.8M |
| Gross profit | $345.2M | $309.4M | $345.8M | $328.6M |
| What it spent | ||||
| Research and development | $65.7M | $62.9M | $61.2M | $71.4M |
| Sales and admin | $221.0M | $212.4M | $212.0M | $257.1M |
| Other operating costs | -$4.4M | — | — | $49.8M |
| Total operating expenses | $282.3M | $275.3M | $273.2M | $378.3M |
| What was left | ||||
| Operating profit | $61.9M | $34.1M | $72.6M | -$49.7M |
| Interest on debt | $12.1M | $12.3M | $12.1M | $12.3M |
| Profit before tax | $929.2M | -$689.8M | $542.1M | $538.7M |
| Tax | $209.2M | -$162.7M | $170.7M | $80.1M |
| Net profit | $720.0M | -$527.1M | $371.4M | $458.6M |
| EBITDA | $983.8M | -$636.6M | $542.1M | $592.2M |
This stock is trending upward.
Trend
Constructive
60 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage leans bearish
BIO.B SEC Filings, Apr-May 2026 - BIO-RAD LABORATORIES, INC. Filing Archive
BearishNov 8BIO.B SEC Filings - BIO-RAD LABORATORIES, INC. 10-K, 10-Q, 8-K Forms
NeutralNov 5Bio-Rad Laboratories FY26 Results: Sales guidance affirmed at $2.51B-$2.60B
NeutralNov 5BIO.B SEC Filings, May-Sep 2026 - BIO-RAD LABORATORIES, INC. Filing Archive
NeutralOct 3112 macro signals shaping BIO right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results
